LILRB4 and leukemia: Notably, in leukemia, inhibition or reduction of FTO expression blocks leukocyte immunoglobulin-like receptor B4, an immune checkpoint gene expression, inhibits the self-renewal ability of stem cells, while enhancing leukemia sensitivity to drugs and preventing the development of immune evasion [237].